Beqalzi (Sonrotoclax) FDA Approval: BCL-2 Inhibitor for MCL
Examine the FDA accelerated approval of Beqalzi (sonrotoclax), the first BCL-2 inhibitor for relapsed mantle cell lymphoma, including efficacy and safety data.
Back to Articles
Articles tagged with “beqalzi”